A Phase 1/2 Study Exploring the Safety Tolerability and Efficacy of INCAGN01949 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Brief description of study
If you have been diagnosed with advanced cancer or cancer that has metastasized (spread to other parts of the body), you may be qualified for this Phase 1/2 study. The main goal of this study is to see if the combination of an investigational drug, INCAGN01949, with nivolumab and/or ipilimumab (administered either together or one after the other) is safe, able to be tolerated, and works well for people with advanced cancer or cancer that has metastasized.
Clinical Study Identifier: s17-00967
ClinicalTrials.gov Identifier: NCTs17-00967
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
